Современные медикаментозные методы лечения табакокурения
Аннотация
Курение представляет собой весьма значимый фактор риска сердечно-сосудистых, респираторных и онкологических заболеваний. На сегодняшний день в арсенале врача существует ряд препаратов для медикаментозной поддержки отказа от курения. В обзоре представлены последние данные, касающиеся сравнительной эффективности и безопасности современных методов лечения никотиновой зависимости, в том числе у пациентов высокого риска.
Об авторе
А. В. Родионов
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский университет)
Россия
к.м.н.
Россия
к.м.н.
Список литературы
1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004 Sep 11-17, 364(9438): 937-952.
2. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P et al., INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 2010 Jul 10, 376(9735): 112-123.
3. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. European Heart Journal, 2013, 34: 3259-3267.
4. Faber T, Kumar A, Mackenbach JP, Millett C, Basu S, Sheikh A, Been JV. Effect of tobacco control policies on perinatal and child health: a systematic review and meta-analysis. Lancet Public Health, 2017 Sep 5, 2(9): e420-e437.
5. Hackshaw A et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ, 2018 Jan 24, 360: j5855.
6. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 2016 Aug 1, 37(29): 2315-2381.
7. Silagy C, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev, 2001, 2.
8. Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual Versus Abrupt Smoking Cessation: A Randomized, Controlled Noninferiority Trial. Ann Intern Med, 2016 May 3, 164(9): 585-592. doi: 10.7326/M14-2805.
9. Smoking: harm reduction. Smoking: harm reduction. Public health guideline. Published: 5 June 2013. nice.org.uk/guidance/ph4.
10. The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American journal of preventive medicine, 2008, 35(2): 158-176.
11. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2004, 3.
12. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2007 Jan 24, 1.
13. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R et al. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes, 2017 Jan, 10(1).
14. Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, 2016 Feb 22, 5(2).
15. Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med, 2015 Oct, 3(10): 761-768.
16. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016 Jun 18, 387(10037): 2507-2520.
17. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation, 2016 Jan 5, 133(1): 21-30.
18. Kotz D, Viechtbauer W, Simpson CR, van Schayck OCP, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax, 2017 May 4. pii: thoraxjnl-2017-210067.
Для цитирования:
Родионов А.В. Современные медикаментозные методы лечения табакокурения. Медицинский Совет. 2018;(5):100-103. https://doi.org/10.21518/2079-701X-2018-5-100-103
For citation:
Rodionov A.V. Modern pharmaceutical methods of treatment of tobacco smoking. Meditsinskiy sovet = Medical Council. 2018;(5):100-103. (In Russ.) https://doi.org/10.21518/2079-701X-2018-5-100-103
Просмотров: 240
Послать статью по эл. почте 
